Clinicopathological features of the overall cohort
| Clinicapathological features, n=92 | Median (Q1–Q3) | % (n) | |
| Age at diagnosis, years, median (Q1–Q3) | 51 (44–62) | ||
| Menopausal status, % (n) | Premenopausal | – | 46.7 (43) |
| Postmenopausal | – | 50.0 (46) | |
| NA | – | 3.3 (3) | |
| Clinical stage at diagnosis (AJCC), % (n) | II | – | 38.1 (35) |
| III | – | 59.8 (55) | |
| NA | – | 2.1 (2) | |
| Histotype, % (n) | Ductal (NST) | – | 68.5 (63) |
| Lobular | – | 26.1 (24) | |
| Other | – | 3.3 (3) | |
| NA | – | 2.1 (2) | |
| Baseline tumour grade, % (n) | 1 | – | 2.1 (2) |
| 2 | – | 35.9 (33) | |
| 3 | – | 41.4 (38) | |
| NA | – | 20.6 (19) | |
| Baseline ER expression, %, median (Q1–Q3) | 90 (70–90) | – | |
| Baseline PgR expression, %, median (Q1–Q3) | 55 (5–80) | – | |
| Baseline Ki67 expression, %, median (Q1–Q3) | 27 (18–40) | – | |
| Tumour phenotype | ER+/PgR+ | 70.6 (65) | |
| ER+/PgR- | 27.2 (25) | ||
| ER−/PgR+ | 0.0 (0) | ||
| NA | 2.2 (2) | ||
| Neoadjuvant chemotherapy, % (n) | Anthracycline-taxane | – | 93.5 (86) |
| Anthracyline | – | 6.5 (6) | |
| RD-ER expression, %, median (Q1–Q3) | 90 (80–90) | – | |
| RD-PgR expression, %, median (Q1–Q3) | 30 (5–70) | – | |
| RD-Ki67 expression, %, median (Q1–Q3) | 12 (5–23) | – | |
| Adjuvant chemotherapy, % (n) | – | 22.8 (21) | |
| Adjuvant endocrine therapy, % (n) | – | 96.7 (89) | |
| Endocrine therapy, type, % (n) | Tamoxifene | – | 32.6 (29) |
| Aromatase inhibithor | – | 39.3 (35) | |
| Switch | – | 28.1 (25) | |
| Disease recurrence, % (n) Isolated local relapse Distant relapse | – | 45.7 (42) | |
| – | 6.5 (6) 42.4 (39) | ||
| RCB score, median (Q1–Q3) | 3.364 (2.311–3.944) | ||
| RCB class, % (n) | 1 | – | 3.3 (3) |
| 2 | – | 39.1 (36) | |
| 3 | – | 48.9 (45) | |
| NA | – | 8.7 (8) | |
AJCC, American Joint Committee on Cancer; ER, oestrogen receptor; NA, not available; NST, no-special type; PgR, progesterone receptor; RCB, residual cancer burden; RD, residual disease.